These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14704591)

  • 1. Effect of pefloxacin on the urinary excretion of rifampicin.
    Orisakwe OE; Agbasi PU; Ofoefule SI; Ilondu NA; Afonne OJ; Anusiem CA; Ilo CE; Maduka SO
    Am J Ther; 2004; 11(1):13-6. PubMed ID: 14704591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin.
    Orisakwe OE; Akunyili DN; Agbasi PU; Ezejiofor NA
    Am J Ther; 2004; 11(4):283-7. PubMed ID: 15266220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of rifampicin in the presence of ciprofloxacin.
    Orisakwe OE; Afonne OJ; Agbasi PU; Ofoefule SI
    Am J Ther; 2004; 11(3):171-4. PubMed ID: 15133531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampicin pharmacokinetics with and without ciprofloxacin.
    Orisakwe OE; Agbasi PU; Afonne OJ; Ofoefule SI; Obi E; Orish CN
    Am J Ther; 2001; 8(3):151-3. PubMed ID: 11344382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G; Ellard GA; Smith PJ; Fourie PB
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pefloxacin on urinary and salivary concentrations of isoniazid in six healthy female volunteers.
    Ofoefule SI; Onyeagba OE; Orisakwe OE
    Am J Ther; 2000 Sep; 7(5):313-6. PubMed ID: 11317177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of rifampin on the pharmacokinetics of pefloxacin.
    Humbert G; Brumpt I; Montay G; Le Liboux A; Frydman A; Borsa-Lebas F; Moore N
    Clin Pharmacol Ther; 1991 Dec; 50(6):682-7. PubMed ID: 1752112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 10. Rifampicin causes false-positive immunoassay results for urine opiates.
    de Paula M; Saiz LC; González-Revaldería J; Pascual T; Alberola C; Miravalles E
    Clin Chem Lab Med; 1998 Apr; 36(4):241-3. PubMed ID: 9638350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
    Lewin CS; Amyes SG
    J Med Microbiol; 1990 Jun; 32(2):83-6. PubMed ID: 1693968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report: pharmacokinetic and drug interaction studies of pefloxacin with paracetamol (NNAID) in healthy volunteers in Pakistan.
    Gauhar S; Ali SA; Naqvi SB; Shoaib MH
    Pak J Pharm Sci; 2014 Mar; 27(2):389-95. PubMed ID: 24577931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
    Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ
    Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between ciprofloxacin and rifampin.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999; 33(7-8):868-70. PubMed ID: 10466918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenomenon of rifampicin-induced discolouration of body fluids.
    Morgan JR; Clarke KW; Brear SG
    Respir Med; 1993 May; 87(4):320-1. PubMed ID: 9728237
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of enoxacin, norfloxacin and pefloxacin on polymorphonuclear leukocytes chemiluminescence.
    Aquilini D; Bartoloni A; Paradisi F
    J Chemother; 1991 Jan; 3 Suppl 1():116-8. PubMed ID: 12041743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.